"We designed our dual-antigen test to ensure the best possible specificity without loss in the sensitivity of the test." - Dr. Maria Kireeva, VirIntel
FREDERICK, Md. (PRWEB) September 17, 2020
VirIntel, LLC has developed and commercialized a COVID-19 antibody test with demonstrated 100% specificity and 94% sensitivity in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The VirIntel COVID-19 Antibody Test measures antibodies against two viral proteins, a receptor-binding domain (RBD) of spike glycoprotein and nucleocapsid protein N, thus decreasing and eliminating false positive results. RBD is considered to be the primary target for neutralizing antibodies against SARS-CoV-2. Neutralizing antibodies inhibit infection of human cells by SARS-CoV-2.
Dr. Maria Kireeva, head scientist at VirIntel comments, “We designed our dual-antigen test to ensure the best possible specificity without loss in the sensitivity of the test. Furthermore, this is part of our broader approach to developing tests that measure antibodies against multiple viral proteins and antigens as the means to evaluate the level of protection offered by the immune system.”
The VirIntel COVID-19 Antibody Test requires a blood draw at the point of care and the results can be analyzed by any laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA), a federal government standard for ensuring quality laboratory testing of humans.
The test is not available for home testing.
About VirIntel, LLC
VirIntel is a privately-held biotechnology company pursuing the goal of immunity intelligence. VirIntel and its executive team have a successful track record of partnerships with global companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services.
To learn more please visit: http://www.virintel.com or contact Vladimir Litvak at Vladimir.Litvak@virintel.com